P2Y12 antagonism results in altered interactions between platelets and regulatory T cells during sepsis
- 26 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 110 (1) , 141-153
Abstract
Sepsis is a complex clinical condition resulting from a serious bloodstream infection. With mortality rates as high as 50%, improved treatments are needed. Regulatory T cells (Tregs), a subset of T lymphocytes, promote the resolution of inflammation. Septic patients have elevated levels of circulating Tregs. Platelets influence the proliferation and activation of Tregs in vitro. However, modulating platelet‐Tregs interaction during sepsis may restraing Treg proliferation, leading to the restoration of immunologic homeostasis. P2Y12 is a purinergic receptor present on platelets and T lymphocytes. Blocking P2Y12 improves the outcome of sepsis. We investigated whether blocking P2Y12 alters platelet–Treg interaction in vivo. We used the murine model of sepsis, cecal ligation, and puncture (CLP) and we blocked P2Y12 using the P2Y12 antagonist, clopidogrel. Twenty‐four hours after surgery, we measured Treg population sizes in the spleens of the Sham, CLP, and CLP + clopidogrel groups. We investigated the effect of blocking P2Y12 in vitro using cocultures of human platelets and T cells with or without anti‐CD3/CD28. P2Y12 was blocked using AR‐C69931MX. Treg population sizes were reduced in the septic mice treated with clopidogrel compared with untreated septic mice. Aggregation of platelets and CD4+ T cells was reduced in treated CLP mice compared with untreated CLP mice. P2Y12 antagonism changes how platelets influence T cells in vitro, depending on T‐cell activation. In conclusion, blockade of the P2Y12 signaling pathway restrains Treg proliferation in vivo and in vitro. Targeting platelets to control Treg proliferation and activity may be a promising strategy for treating sepsis.Keywords
This publication has 44 references indexed in Scilit:
- Functional consequences of platelet binding to T lymphocytes in inflammationJournal of Leukocyte Biology, 2013
- Foxp3+ Regulatory T Cells Are Required for Recovery from Severe SepsisPLOS ONE, 2013
- Platelets: a critical link between inflammation and microvascular dysfunctionThe Journal of Physiology, 2012
- Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune diseaseNature Medicine, 2011
- Adenosine Diphosphate Receptor Antagonist Clopidogrel Sulfate Attenuates LPS-Induced Systemic Inflammation in a Rat ModelShock, 2011
- P2Y12 receptor in platelet activationPlatelets, 2010
- The role of T‐regulatory cells and Toll‐like receptors in the pathogenesis of human inflammatory bowel diseaseImmunology, 2008
- The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune diseaseClinical and Experimental Immunology, 2007
- Regulatory T Cells and Human DiseaseJournal of Immunology Research, 2007
- Regulatory T cells in human disease and their potential for therapeutic manipulationImmunology, 2006